ANN ARBOR, Mich. – Akadeum Life Sciences is demonstrating the broad integration capabilities of its microbubble-based cell separation technology at the ASGCT 2025 Annual Meeting. The company’s innovative approach enables more scalable and cost-effective cell therapy manufacturing while maintaining cell health and viability.
Streamlining Cell Therapy Production
Akadeum’s buoyancy-based technology significantly reduces the physical footprint required for cell isolation processes. The platform’s compatibility with existing systems allows for both centralized and decentralized manufacturing setups, addressing critical challenges in cell therapy scale-up.
Key Presentations at ASGCT
The conference features multiple demonstrations of Akadeum’s technology:
- Charles River Laboratories will present data showing superior T cell isolation compared to magnetic methods
- Lonza will showcase integration results using Akadeum’s kit on their Cocoon® Platform
- Akadeum scientists will present workflow integration data during networking sessions
Industry Partnerships Accelerate Adoption
“By collaborating with leaders like Charles River and Lonza, we’re proving our technology’s versatility across different platforms and applications,” said an Akadeum spokesperson. The company is offering an Evaluation Program allowing researchers to test the technology in their own labs with expert support.
Advancing Cell Therapy Manufacturing
Akadeum’s GMP-grade microbubble products support process development for next-generation therapies. The technology’s ability to maintain cellular phenotypes while improving purity and recovery positions it as a potential game-changer for CAR-T and other advanced therapies.
Related Topics: